Landscapes / Companies
Coherus Oncology, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
5
in active trials · 9 in all
Trials
6 active
11 since 2021
Drugs5
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Programmed death receptor-1 blocking antibody |
Approved | Sep 2027Phase 2 trial completes | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma and 4 more | ||||
| Open drug page | |||||
Unmodified immunoglobulin |
Phase 2 | Sep 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma | ||||
| Open drug page | |||||
Pasritamignot checked |
Multi-specific immunoglobulin |
Phase 1/2 | Aug 2028Phase 1/2 trial completes | ||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | Aug 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor | ||||
| Open drug page | |||||
Tagmokitugnot checked |
Unmodified immunoglobulin |
Phase 1/2 | Aug 2028Phase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | Aug 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | 30 May 2028Phase 1 trial completes | |||
| Next date | 30 May 2028 · Phase 1 trial completes | ||||
| Also tested for | Advanced or Metastatic Solid Tumors | ||||
| Open drug page | |||||
About
- No active trial
- CHS-006, etrumadenant, SRF617, zimberelimab
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021